HilleVax, Inc. is poised for its IPO on April 29, 2022. The stock, ticker HLVX, offers an exciting biotech investment opportunity. Experts predict its potential worth could exceed $100 billion with FDA approval. Our in-depth analysis reveals the stock's promising future, making it a top pick for long-term investors. Don't miss out on this once-in-a-lifetime opportunity!